Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 2/20 | 0.49 |
| ▸ | CNR2 | P34972 | 2/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.48 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL947428 | 1.00 | CYP2D6 (0.52) | CYP2D6PLA2G4BKDM4ES1PR5MAPK1 | |
| Trifluoroacetic Acid SCHEMBL947515 | 1.00 | CYP2D6 (0.52) | CYP2D6PLA2G4BKDM4ES1PR5MAPK1 | |
| Trifluoroacetic Acid SCHEMBL949073 | 1.00 | CYP2D6 (0.52) | CYP2D6PLA2G4BKDM4ES1PR5MAPK1 | |
| Trifluoroacetic Acid SCHEMBL948049 | 1.00 | CYP2D6 (0.52) | CYP2D6PLA2G4BKDM4ES1PR5MAPK1 | |
| Trifluoroacetic Acid SCHEMBL948327 | 0.99 | KDM4E (0.51) | CYP2D6PLA2G4BKDM4ES1PR5MAPK1 | |
| Trifluoroacetic Acid SCHEMBL947421 | 0.96 | KDM4E (0.51) | CYP2D6PLA2G4BKDM4EMAPK1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL947011 | 0.91 | CYP2D6 (0.61) | CYP2D6PLA2G4BKDM4ES1PR5ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL948823 | 0.91 | CYP2D6 (0.61) | CYP2D6PLA2G4BKDM4ES1PR5ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL949915 | 0.91 | CYP2D6 (0.61) | CYP2D6PLA2G4BKDM4ES1PR5ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL947789 | 0.91 | CYP2D6 (0.61) | CYP2D6PLA2G4BKDM4ES1PR5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2883865-A1 | Compound capable of binding S1P receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-17 | — | — | EP | disclosed |
| US-20140288034-A1 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-09-25 | — | — | US | disclosed |
| US-8791159-B2 | Compound capable of binding S1P receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-07-29 | — | — | US | disclosed |
| US-20110020324-A1 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD (JP) | 2011-01-27 | — | — | US | disclosed |
| US-7825109-B2 | Compound capable of binding S1P receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-11-02 | — | — | US | disclosed |
| CN-101407471-A | Compound capable of binding S1P receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO (JP) | 2009-04-15 | — | — | CN | disclosed |
| US-20070167425-A1 | Compound capable of binding s1p receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1661881-A2 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288034-A1 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | S1PR1, S1PR2, S1PR3 | CYP2D6 1819/4885PLA2G4B 281/4885KDM4E 2041/4885 |
| US-20070167425-A1 | Compound capable of binding s1p receptor and pharmaceutical use thereof | S1PR1, S1PR3, S1PR2 | CYP2D6 594/4885PLA2G4B 218/4885KDM4E 1286/4885 |
| US-20110020324-A1 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | S1PR1, S1PR3, S1PR2 | CYP2D6 594/4885PLA2G4B 218/4885KDM4E 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.